211245-62-4

Basic information

• Product Name: 4-CYCLOPENTYLAMINO-2-METHYLSULFANYL-PYRIMIDINE-5-CARBOXYLIC ACID ETHYL ESTER
• Synonyms: 4-CYCLOPENTYLAMINO-2-METHYLSULFANYL-PYRIMIDINE-5-CARBOXYLIC ACID ETHYL ESTER;Ethyl 4-cyclopentylamino-2-methylsulfanylpyrimidine-5-carboxylate;4-(Cyclopentylamino)-2-(methylthio)-5-pyrimidinecarboxylic acid ethyl ester;ethyl 4-(cyclopentylamino)-2-(methylthio)pyrimidine-5-carboxylate;4-(Cyclopentylamino)-2-(Methylthio)-5-Pyrimidinecarboxylic Acid Ethyl Ester(WX687914);5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-2-(methylthio)-, ethyl ester
• CAS NO: 211245-62-4
• Molecular Formula: C₁₃H₁₉N₃O₂S
• Molecular Weight: 281.37386
• EINECS: 1533716-785-6
• Mol File: 211245-62-4.mol

Chemical Properties

• Boiling Point: 434.9±25.0 °C(Predicted)
• Appearance: /
• Density: 1.22±0.1 g/cm3(Predicted)
• PKA: 3.00±0.10(Predicted)
• CAS DataBase Reference: 4-CYCLOPENTYLAMINO-2-METHYLSULFANYL-PYRIMIDINE-5-CARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CYCLOPENTYLAMINO-2-METHYLSULFANYL-PYRIMIDINE-5-CARBOXYLIC ACID ETHYL ESTER(211245-62-4)
• EPA Substance Registry System: 4-CYCLOPENTYLAMINO-2-METHYLSULFANYL-PYRIMIDINE-5-CARBOXYLIC ACID ETHYL ESTER(211245-62-4)

Safety Data

• Hazardous Substances Data: 211245-62-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Cyclopentylamino-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester is used as a building block in the synthesis of pharmaceuticals for its potential role in the development of new drugs. Its specific properties and functional groups make it a valuable component in the creation of innovative therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 4-Cyclopentylamino-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester is utilized as a precursor in the synthesis of agrochemicals, particularly in the development of new pesticides. Its chemical structure and functional groups contribute to the formulation of effective and targeted pest control solutions.

InChI:InChI=1S/C13H19N3O2S/c1-3-18-12(17)10-8-14-13(19-2)16-11(10)15-9-6-4-5-7-9/h8-9H,3-7H2,1-2H3,(H,14,15,16)

Upstream product

• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 
• 1003-03-8 Cyclopentamine 

Downstream Products

• 1357470-37-1 8-cyclopentyl-6-methylsulfonyl-2-[4-(4-methyl-piperazin-1-yl)phenylamino]-8H-pyrido[2, 3-d]pyrimidin-7-one 
• 1312471-74-1 6-benzenesulfonyl-8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)phenylamino]-8H-pyrido[2,3-d]pyrimidine-7-one 
• 1312471-68-3 6-(4-chlorobenzenesulfonyl)-8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)phenylamino]-8H-pyrido[2,3-d]pyrimidine-7-one 
• 1312471-77-4 6-benzenesulfonyl-8-cyclopentyl-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1312471-70-7 6-(4-chlorobenzenesulfonyl)-8-cyclopentyl-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1312471-76-3 6-benzenesulfonyl-8-cyclopentyl-2-methylsulfinyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 1312471-69-4 6-(4-chloro-benzenesulfonyl)-8-cyclopentyl-2-methylsulfinyl-8Hpyrido[2,3-d]pyrimidin-7-one 
• 1537215-25-0 8-cyclopentyl-2-(2-methoxyphenylamino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile 
• 1357470-32-6 8-cyclopentyl-2-(3,5-dimethoxyphenylamino)-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile 
• 1357470-34-8 8-cyclopentyl-2-(3,4,5-trimethoxyphenylamino)-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile 
• 89381-13-5 trans-2-hydroxycyclopentylamine 
• 362656-11-9 1-(4-cyclopentylamino-2-methylsulfanylpyrimidin-5-yl)ethanone 
• 362656-25-5 6-bromo-8-cyclopentyl-5-methyl-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 571190-30-2 PD 0332991 

Relevant articles and documents

4-substituted pyrido [2, 3-d] pyrimidine-7-ketone compound as well as preparation method and application thereof

The invention discloses 4-substituted pyrido [2, 3-d] pyrimidine-7-ketone compounds with different general formula structures and pharmaceutically acceptable salts, solvates, polymorphic substances, tautomers, metabolites or prodrugs of the 4-substituted pyrido [2, 3-d] pyrimidine-7-ketone compounds. The invention also discloses an effect of the compound as an NEDD8 activating enzyme inhibitor and an application of the compound in preparation of drugs for treating diseases related to NEDD8 activating enzyme abnormality. Pharmacological results show that the compound has good NEDD8 inhibitory activity, tumor cell proliferation resistance and tumor cell apoptosis promotion effects.

Coumarin compounds as well as preparation method and application thereof

The invention discloses coumarin compounds with different general formula structures and pharmaceutically acceptable salts, solvates, polymorphic substances, tautomers, metabolites or prodrugs thereof. The invention also discloses an effect of the compound as an NEDD8 activating enzyme inhibitor and an application of the compound in preparation of drugs for treating diseases related to NEDD8 activating enzyme abnormality. The invention also discloses an intermediate for preparing the coumarin compound and a preparation method thereof. Pharmacological results show that the compound has high NEDD8 inhibitory activity, tumor cell proliferation resistance and tumor cell apoptosis promotion effects.

Generating Selective Leads for Mer Kinase Inhibitors-Example of a Comprehensive Lead-Generation Strategy

Mer is a member of the TAM (Tyro3, Axl, Mer) kinase family that has been associated with cancer progression, metastasis, and drug resistance. Their essential function in immune homeostasis has prompted an interest in their role as modulators of antitumor immune response in the tumor microenvironment. Here we illustrate the outcomes of an extensive lead-generation campaign for identification of Mer inhibitors, focusing on the results from concurrent, orthogonal high-throughput screening approaches. Data mining, HT (high-throughput), and DECL (DNA-encoded chemical library) screens offered means to evaluate large numbers of compounds. We discuss campaign strategy and screening outcomes, and exemplify series resulting from prioritization of hits that were identified. Concurrent execution of HT and DECL screening successfully yielded a large number of potent, selective, and novel starting points, covering a range of selectivity profiles across the TAM family members and modes of kinase binding, and offered excellent start points for lead development.

HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS

Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES AS CDK INHIBITORS

The pyrido[2,3-d]pyrimidin-7(8H)-ones of Formula (1) and pharmaceutical compositions containing compounds of Formula (1) as CDK inhibitors are disclosed herein. Methods and use of a compound of Formula 1 in the treatment of cancer and manufacture are also disclosed.

Structure optimization of positive allosteric modulators of GABAB receptors led to the unexpected discovery of antagonists/potential negative allosteric modulators

Positive allosteric modulators (PAMs) of GABAB receptor represent an interesting alternative to receptor agonists such as baclofen, as they act on the receptor in a more physiological way and thus are devoid of the side effects typically exerted by the agonists. Based on our interest in the identification of new GABAB receptor PAMs, we followed a merging approach to design new chemotypes starting from selected active compounds, such as GS39783, rac-BHFF, and BHF177, and we ended up with the synthesis of four different classes of compounds. The new compounds were tested alone or in the presence of 10 μM GABA using [35S]GTPγS binding assay to assess their functionality at the receptor. Unexpectedly, a number of them significantly inhibited GABA-stimulated GTPγS binding thus revealing a functional switch with respect to the prototype molecules. Further studies on selected compounds will clarify if they act as negative modulators of the receptor or, instead, as antagonists at the orthosteric binding site.

Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6

The presently disclosed subject matter relates to methods and compositions for protecting cells and or tissues from damage due to ischemia. In particular, the presently disclosed subject matter relates to the protective action of cyclin dependent kinase 4/6 (CDK4/6) inhibitors administered to subjects that have been exposed to, or that are at risk of, ischemia.

CYCLIN DEPENDENT KINASE INHIBITORS AND METHODS OF USE

The presently disclosed subject matter relates to methods and compositions for protecting healthy cells from damage due to DNA damaging agents. In particular, the presently disclosed subject matter relates to the protective action of selective cyclin dependent kinase 4/6 (CDK4/6) inhibitors administered to subjects that have been exposed to or that are at risk of exposure to DNA damage.

Pyrimidine or pyridine pyridine ketone compound and its preparation method and application (by machine translation)

The invention discloses a kind of type I of the pyrimidine or pyridine pyridine ketone compound and its preparation and application, which belongs to the technical field of pharmaceutical preparation. The compounds have high-efficient and selectively inhibit the cell cycle dependent kinases (Cdks) CDK4 and CDK6 active, and then by inhibiting CDK4/CDK6 prevent tumor cell division. Therefore, the compounds of this invention can be used for CDK4 and CDK6 the involved in cell cycle control disorders result in various diseases, especially suitable for the treatment of malignant tumors. (by machine translation)

Pyridopyrimidinone derivatives as potent and selective c-jun N-terminal kinase (JNK) inhibitors

A novel series of 2-aminopyridopyrimidinone based JNK (c-jun N-terminal kinase) inhibitors were discovered and developed. Structure-activity relationships (SARs) were systematically developed utilizing biochemical and cell based assays and in vitro and in vivo drug metabolism and pharmacokinetic (DMPK) studies. Through the optimization of lead compound 1, several potent and selective JNK inhibitors with high oral bioavailability were developed. Inhibitor 13 was a potent JNK3 inhibitor (IC50 = 15 nM), had high selectivity against p38 (IC50 > 10 μM), had high potency in functional cell based assays, and had high stability in human liver microsome (t1/2 = 76 min), a clean CYP-450 inhibition profile, and excellent oral bioavailability (%F = 87). Moreover, cocrystal structures of compounds 13 and 22 in JNK3 were solved at 2.0 ?. These structures elucidated the binding mode (Type-I binding) and can pave the way for further inhibitor design of this pyridopyrimidinone scaffold for JNK inhibition.